Provided by Tiger Fintech (Singapore) Pte. Ltd.

Prime Medicine, Inc.

3.74
-0.1800-4.59%
Pre-market: 3.860.1200+3.21%06:31 EDT
Volume:8.63M
Turnover:32.14M
Market Cap:490.03M
PE:-2.32
High:3.91
Open:3.62
Low:3.52
Close:3.92
Loading ...

Company Profile

Company Name:
Prime Medicine, Inc.
Exchange:
NASDAQ
Establishment Date:
2019
Employees:
214
Office Location:
60 First Street,Cambridge,Massachusetts,United States
Zip Code:
02141
Fax:
- -
Introduction:
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.

Directors

Name
Position
Jeffrey D. Marrazzo
Executive Chairman of the Board
David Schenkein
Independent Director
Kaye Foster
Independent Director
Michael Kelly
Independent Director
Robert Taylor NELSEN
Independent Director
Thomas Cahill
Independent Director
Wendy Chung
Independent Director

Shareholders

Name
Position
Allan Reine
Chief Executive Officer and Chief Financial Officer
Carman Alenson
Senior Vice President, Finance and Chief Accounting Officer
Meredith Goldwasser
Senior Vice President, Strategy and Corporate Operations
Andrew Anzalone
Head of Prime Editing Platform
Ann Lee
Chief Technical Officer
Jeffrey D. Marrazzo
Executive Chairman of the Board
Richard Brudnick
Chief Business Officer